Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Previously Presented) A compound of formula (I):



(I)

wherein:

R^1 represents a group selected from:











each ring of which optionally includes a further heteroatom N,

Z represents an optional substituent halogen,
alk represents alkylene or alkenylene,
T represents S, O or NH;

R^2 represents hydrogen, -C_{1-6}alkyl, -C_{1-3}alkylCONR^{a}R^b, -C_{1-3}alkylCO_2C_{1-4}alkyl, -CO_2C_{1-4}alkyl or -C_{1-3}alkylCO_2H;

R^a and R^b independently represent hydrogen, -C_{1-6}alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally consisting of an additional heteroatom selected from O, N or $S(O)_n$, optionally substituted by -C_{1-4}alkyl;

n represents 0-2;

X represents phenyl or a 5- or 6- membered aromatic heterocyclic group consisting of at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -C_{1-4}alkyl, -C_{2-4}alkenyl, -CN, -CF_3, -NR^{a}R^b, -C_{0-4}alkylOR^e, -C(O)R^f and -C(O)NR^{a}R^b;

R^e represents hydrogen or -C_{1-6}alkyl;
R^f represents -C_{1-6}alkyl;

Y represents phenyl or a 5- or 6- membered aromatic heterocyclic group consisting of at least one heteroatom selected from O, N or S, each of which is substituted by a group –C_{1-2}alkylNR^{c}R^d.

R^c and R^d, together with the nitrogen atom to which they are bonded, form a 4-membered heterocyclic ring optionally substituted by halogen, OH or –OC_{1-6}alkyl, or a 5- or 6- membered non-aromatic heterocyclic ring substituted by OH, –OC_{1-6}alkyl or 1 to 2 halogens, with the proviso that the substituent is not attached to a ring carbon atom adjacent to a heteroatom;

or pharmaceutically acceptable derivative thereof.

2. (Original) A compound according to claim 1 wherein R^1 represents a group selected from:



each ring of which optionally includes a further heteroatom N,
Z represents an optional substituent halogen,
alk represents alkylene or alkenylene,
T represents S, O or NH;
or pharmaceutically acceptable derivative thereof.

3. (Previously Presented) A compound according to claim 1 wherein R^2 represents hydrogen or pharmaceutically acceptable derivative thereof.

4. (Previously Presented) A compound according to claims 1 wherein X represents phenyl or a 5 or 6 membered aromatic heterocyclic group consisting of at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, $-C_{1-4}$alkyl or $-NR^aR^b$ or pharmaceutically acceptable derivative thereof.

5. (Previously Presented) A compound according to claim 1 wherein Y represents a 5 or 6 membered aromatic heterocyclic group consisting of at least one heteroatom selected from O, N or S, each of which is substituted by a group $-CH_2NR^cR^d$ or pharmaceutically acceptable derivative thereof.

6. (Previously Presented) A compound selected from:
(1*E*)-*N*-(1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-2-(5-chloro-2-thienyl)-1-propene-1-sulfonamide;

N-(1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-2-(5-chloro-2-thienyl)ethanesulfonamide;
N-((3*S*)-1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-6-chloro-1-benzothiophene-2-sulfonamide;
(*E*)-2-(5-Chloro-2-thienyl)-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]ethenesulfonamide;
(1*E*)-2-(5-Chloro-2-thienyl)-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]-1-propene-1-sulfonamide;
6-Chloro-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]-1-benzothiophene-2-sulfonamide; and
6-Chloro-*N*-{1-[2-fluoro-4-(2-{[3-(methyloxy)-1-azetidinyl]methyl}-1*H*-imidazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl}-1-benzothiophene-2-sulfonamide formate;
or a pharmaceutically acceptable derivative thereof.

7. (Cancelled).

8. (Previously Presented) A pharmaceutical composition comprising a compound according to claims 1 or a pharmaceutically acceptable derivative thereof together with at least one pharmaceutical carrier or excipient.

9. (Cancelled).

10. (Currently Amended) A method of treating a ~~patient suffering from a~~ condition susceptible to amelioration by a Factor Xa inhibitor, wherein said condition is one or more of acute coronary syndromes, prothrombotic sequalae associated with myocardial infarction or heart failure, thromboembolism, acute vessel closure associated with thrombolytic therapy and percutaneous transluminal coronary angioplasty, transient ischemic attacks, pulmonary embolism, deep vein thrombosis, peripheral arterial occlusion, restenosis, and thromboembolic events associated with atrial fibrillation including stroke, comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable derivative thereof.

11. (Currently Amended) A process for preparing a compound ~~of formula (I)~~ as claimed in claim 1, which comprises:

(a) reacting a compound of formula (II) or an acid addition salt thereof with a compound of formula (III) where V is a suitable leaving group:



(II)



(III)

OR:

(b) by reacting compounds of formula (I) where R^2 is hydrogen with compounds of formula (XI):



(XI)

wherein R^2 is -C_{1-6}alkyl, -C_{1-3}alkylCONR^{a}R^b, -C_{1-3}alkylCO_2C_{1-4}alkyl, or -CO_2C_{1-4}alkyl and T is a suitable leaving group, optionally followed by removal of the alkyl protecting group where appropriate.